[PDF] Top 20 Addition of incretin therapy to metformin in type 2 diabetes.

... end of follow-up (intention to treat, last observation carried forward) versus ...34% of patients on metformin alone. ‡ 27% of patients on metformin ...38% of patients on ... Voir le document complet

... 4. Therapy risk and benefits As the prevalence of type 2 diabetes and the risk of severe side-effects of oral antidiabetic agents are markedly increased with aging, ... Voir le document complet

... second-line therapy behind first-line metformin, as third-line therapy after failure of dual oral therapy or even as add-on to insulin for a majority of patients with ... Voir le document complet

... circumference in a randomised clinical trial in overweight/obese patients with type 2 diabetes treated with metformin (65%) or sulfonylureas (35%) (RIO-Diabetes ...7.3% ... Voir le document complet

... that incretin-based therapies are rather new approaches in the management of T2DM [15] , their PK characteristics in patients with different degrees of HI have been more extensively ... Voir le document complet

... practitioners in the UK. The main result in this study of 48 000 patients with type 2 diabetes (cohort 1 changed from monotherapy to combination oral therapy with ... Voir le document complet

... burden in patients with T2D, potentially improving adherence to, and optimizing the benefits of therapy [15, ...effects of the two compounds were far from being additive and the final ... Voir le document complet

... Administration In the EU, canagliflozin is approved for use as monotherapy (as an adjunct to diet and exercise, when metformin is considered inappropriate) and as an add-on therapy (to ... Voir le document complet

... management of type 2 diabetes. After metformin therapy, and according to the recently updated joint American Diabetes Association (ADA)- European Association for ... Voir le document complet

... Context Metformin is considered as the best initial pharmacological option to lower glucose concentrations in patients with type 2 diabetes mellitus ...As metformin may be ... Voir le document complet

... effect of metformin on blood glucose. In a large cohort of patients with type 2 diabetes, an 80-fold variability in trough steady-state metformin plasma ... Voir le document complet

... shown to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance index and C-reactive protein levels, and to increase high-density lipoprotein (HDL) cholesterol and ... Voir le document complet

... Changes in plasma glucose, insulin, and glucagon in relation to glycaemic response after a liquid meal tolerance test were analyzed during treatment with dual add-on of dapagliflozin plus ... Voir le document complet

... analysis of similar questions answered by both patients and ...participation of persons with T2D in the survey ...acceptance of the survey was high (100%). In addition, the ... Voir le document complet

... add-on therapy and has shown clinically meaningful improvement of glycaemic control in type 2 ...leading to a median >82% DPP-4 inhibition, during 24 weeks in ... Voir le document complet

... prevalence of type 2 diabetes mellitus (T2DM) has reached epidemic proportions worldwide and represents an important threat to global public health ...basis of available clinical ... Voir le document complet

... prescribed metformin treatment at baseline and OA outcome during follow up (adjusted HR = ...However, in a case-control study performed in Taiwan, patients who have OA and T2DM receiving combination ... Voir le document complet

... dose of 1.5 mg once weekly was non-inferior to once-daily ...difference in efficacy derives from differences in dose estimations with the various once-weekly GLP-1 RAs, although ... Voir le document complet

... production in individuals with T2DM through a 25–40% decrease in the hepatic gluconeogenesis rate as determined by 13 C nuclear magnetic resonance (NMR) spectroscopy or tracer infusion 13,14 ...Moreover, ... Voir le document complet

... mechanisms of action that offer improved efficacy and/or better tolerability profiles and can be used either as monotherapy or in combination treatment regimens (including ...class of oral ... Voir le document complet